<DOC>
	<DOCNO>NCT01351597</DOCNO>
	<brief_summary>The purpose study evaluate overall response rate , toxicity , progression free survival quality life chemotherapy docetaxel oxaliplatin recurrent metastatic breast cancer .</brief_summary>
	<brief_title>A Clinical Trial Docetaxel Oxaliplatin Patients With Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>Recent therapeutic development , introduction new cytotoxic agent ( taxanes , platinum , liposomal anthracyclines , etc ) result constant improvement treatment efficacy consequently recurrent metastatic outcome . This single arm , multicenter phase II study design evaluate response rate , toxicity , progression free survival docetaxel oxaliplatin patient recurrence metastatic breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Women age : 20~70 year 2. WHO ( ECOG ) performance status 02 3 . Patients measurable lesion assess image use RECIST ( Response Evaluation Criteria In Solid Tumor ) guideline 4. patient previously receive chemotherapy recurrent metastatic lesion . 5 . Have give write informed consent available prolong followup 1 . Patients previous chemotherapy recurrent breast cancer 2 . Breast cancer recurrence within 12 month taxane treatment 3 . Her2/neu expression breast cancer 4 . Patients malignancy ( breast cancer ) within last 5 year , except adequately treat situ carcinoma cervix basal cell , squamous cell carcinoma skin . 5 . Brain metastasis 6. uncontrolled infection , medically uncontrollable heart disease 7. serious medical illness prior malignancy 8 . Pregnant lactate woman exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>docetaxel</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>